Skip to main content
Journal cover image

An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.

Publication ,  Journal Article
Boyd, M; Mairs, RJ; Keith, WN; Ross, SC; Welsh, P; Akabani, G; Owens, J; Vaidyanathan, G; Carruthers, R; Dorrens, J; Zalutsky, MR
Published in: J Gene Med
August 2004

BACKGROUND: Targeted radiotherapy achieves malignant cell-specific concentration of radiation dosage by tumour-affinic molecules conjugated to radioactive atoms. Combining gene therapy with targeted radiotherapy is attractive because the associated cross-fire irradiation of the latter induces biological bystander effects upon neighbouring cells overcoming low gene transfer efficiency. METHODS: We sought to maximise the tumour specificity and efficacy of noradrenaline transporter (NAT) gene transfer combined with treatment using the radiopharmaceutical meta-[(131)I]iodobenzylguanidine ([(131)I]MIBG). Cell-kill was achieved by treatment with the beta-decay particle emitter [(131)I]MIBG or the alpha-particle emitter [(211)At]MABG. We utilised our novel transfected mosaic spheroid model (TMS) to determine whether this treatment strategy could result in sterilisation of spheroids containing only a small proportion of NAT-expressing cells. RESULTS: The concentrations of [(131)I]MIBG and [(211)At]MABG required to reduce to 0.1% the survival of clonogens derived from the TMS composed of 100% of NAT gene-transfected cells were 1.5 and 0.004 MBq/ml (RSV promoter), 8.5 and 0.0075 MBq/ml (hTR promoter), and 9.0 and 0.008 MBq/ml (hTERT promoter), respectively. The concentrations of radiopharmaceutical required to reduce to 0.1% the survival of clonogens derived from 5% RSV/NAT and 5% hTERT/NAT TMS were 14 and 23 MBq/ml, respectively, for treatment with [(131)I]MIBG and 0.018 and 0.028 MBq/ml, respectively, for treatment with [(211)At]MABG. CONCLUSIONS: These results indicate that the telomerase promoters have the capacity to drive the expression of the NAT. The potency of [(211)At]MABG is approximately three orders of magnitude greater than that of [(131)I]MIBG. Spheroids composed of only 5% of cells expressing NAT under the control of the RSV or hTERT promoter were sterilised by radiopharmaceutical treatment. This observation is indicative of bystander cell-kill.

Duke Scholars

Published In

J Gene Med

DOI

ISSN

1099-498X

Publication Date

August 2004

Volume

6

Issue

8

Start / End Page

937 / 947

Location

England

Related Subject Headings

  • Tumor Cells, Cultured
  • Transgenes
  • Transfection
  • Telomerase
  • Symporters
  • Spheroids, Cellular
  • Radiotherapy
  • Radiopharmaceuticals
  • Promoter Regions, Genetic
  • Plasmids
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boyd, M., Mairs, R. J., Keith, W. N., Ross, S. C., Welsh, P., Akabani, G., … Zalutsky, M. R. (2004). An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med, 6(8), 937–947. https://doi.org/10.1002/jgm.578
Boyd, Marie, Robert J. Mairs, W Nicol Keith, Susan C. Ross, Philip Welsh, Gamal Akabani, Jonathan Owens, et al. “An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.J Gene Med 6, no. 8 (August 2004): 937–47. https://doi.org/10.1002/jgm.578.
Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, Zalutsky MR. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Med. 2004 Aug;6(8):937–947.
Journal cover image

Published In

J Gene Med

DOI

ISSN

1099-498X

Publication Date

August 2004

Volume

6

Issue

8

Start / End Page

937 / 947

Location

England

Related Subject Headings

  • Tumor Cells, Cultured
  • Transgenes
  • Transfection
  • Telomerase
  • Symporters
  • Spheroids, Cellular
  • Radiotherapy
  • Radiopharmaceuticals
  • Promoter Regions, Genetic
  • Plasmids